Zymeworks Inc. Common Shares (ZYME) News

Zymeworks Inc. Common Shares (ZYME): $8.57

0.03 (+0.35%)

POWR Rating

Component Grades








Add ZYME to Watchlist
Sign Up

Industry: Biotech




#118 of 352

in industry

Filter ZYME News Items

ZYME News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ZYME News Highlights

  • For ZYME, its 30 day story count is now at 2.
  • Over the past 11 days, the trend for ZYME's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • DEC, PAR and PRE are the most mentioned tickers in articles about ZYME.

Latest ZYME News From Around the Web

Below are the latest news stories about ZYMEWORKS INC that investors may wish to consider to help them evaluate ZYME as an investment opportunity.

Small-Cap Sensations: 3 Stocks Predicted for Massive Growth in 2024

These three small-cap stocks have massive return potential in 2024 and beyond, according to analyst forecasts and broader industry trends.

Omor Ibne Ehsan on InvestorPlace | December 26, 2023

Zymeworks Announces $50 Million Private Placement to EcoR1 Capital

Proceeds expected to extend cash runway into H2 2027VANCOUVER, British Columbia, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biopharmaceutical company developing novel, multifunctional biotherapeutics, today announced that it had entered into a securities purchase agreement with funds affiliated with EcoR1 Capital, LLC (“EcoR1 Capital”), for the sale of an aggregate of 5,086,521 pre-funded warrants to purchase 5,086,521 shares of common stock, $0.00001 par v

Yahoo | December 26, 2023

From $10k to $100k in 5 years: 3 Small-Cap Stocks to Make a Fortune

Are you looking for small-cap stocks to get rich?

Yiannis Zourmpanos on InvestorPlace | December 25, 2023

Want to Turn Spare Change Into $1,000? Buy These 3 Stocks Now

Three high conviction stocks seem perfect for opportunistic investors and could quickly transform spare change into four-figure returns.

Omor Ibne Ehsan on InvestorPlace | December 18, 2023

Zymeworks Added to Nasdaq Biotechnology Index

VANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). Zymeworks’ addition to the NBI will become effective prior to the market open on Monday, December 18, 2023. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market th

Yahoo | December 15, 2023

Next Wave Biotech: 3 Stocks Poised for Breakthrough Success

The overall sector may be struggling after COVID, but there's still great potential in these three biotech stocks.

Rick Orford on InvestorPlace | December 13, 2023

The 7 Best Bargain Growth Stocks to Buy Before 2024

These bargain growth stocks offer significant upside potential alongside decent margins of safety, for those seeking impressive value.

Omor Ibne Ehsan on InvestorPlace | December 11, 2023

3 Beaten-Down Stocks to Buy for 1,000% Upside in Five Years

Many stocks now trade at tempting valuations, and these three beaten-down stocks could soar 1,000% within five years.

Omor Ibne Ehsan on InvestorPlace | November 30, 2023

Zymeworks Announces Participation in Upcoming Investor Conference

VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: 42nd Annual J.P. Morgan Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on January 8-11, 2024 and a corporate presentation on January 11th, 2024 at 8:15 am Pacific Time. The presentation and web

Yahoo | November 30, 2023

7 Healthcare Stocks That Are Poised to Become the Next Unicorns

Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments.

Chandler Capital on InvestorPlace | November 9, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!